Clinical Trials on Non-Small Cell Lung Adenocarcinoma

Total 15378 results

Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Adult Solid Neoplasm

United States
Clifford Hospital, Guangzhou, China

Completed

Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer (VCONSCLC)

Carcinoma, Non-Small-Cell Lung | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

China
Peking Union Medical College Hospital

Recruiting

A Real-world Study of Durvalumab for Lung Cancer in China

Non Small Cell Lung Cancer Stage III | Small-Cell Lung Cancer

China
University of Maryland, Baltimore
University of Maryland, College Park

Terminated

Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies (0805GCC)

Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Platinum Responsive Malignancies

United States
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Lung Cancer, Nonsmall Cell

United States
Peregrine Pharmaceuticals

Completed

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (SUNRISE)

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Non-Small-Cell Lung Carcinoma | Non-Small-Cell Lung Cancer Stage IIIB | Non-Small-Cell Lung Cancer Stage IV | Non-Small-Cell Lung Cancer Metastatic

United States, Australia, Belgium, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Romania, Russian Federation, Spain, Taiwan, Ukraine
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Elevation Oncology
Merrimack Pharmaceuticals

Terminated

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC (SHERLOC)

Adenocarcinoma | Non-Small Cell Lung Cancer | NSCLC | Heregulin

Spain, Canada, United States, Germany, Hungary, France
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Non Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
Masahiro Tsuboi
Eli Lilly and Company; Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Non-small Cell Lung Cancer Stage II | Non-small Cell Lung Cancer Stage IB | Non-small Cell Lung Cancer Stage ⅢA

Japan
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Rutgers Cancer Institute...

Active, not recruiting

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
Shionogi

Completed

Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer | Stage IIIA Non Small Cell Lung Cancer | Stage IIIB Non Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Synta Pharmaceuticals Corp.

Terminated

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (GALAXY)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

United States, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czech Republic, Germany, Poland, Romania, Russian Federation, Serbia, Spain, United Kingdom
National Cancer Institute (NCI)

Terminated

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer

United States
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Carcinoma, Transitional Cell | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Biliary Tract Cancer | Adenocarcinoma of the Gastroesophageal Junction

Germany, United States, Spain, United Kingdom, France, Japan
University Hospital, Angers
University Hospital, Rouen; Central Hospital, Nancy, France; University Hospital... and other collaborators

Unknown

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient (FLT-THERA)

Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent | No EGFR Activating Mutation

France
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Non Small Cell Lung Cancer | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV | Non Small Cell Lung Cancer Stage IIIA
UNICANCER
National Cancer Institute, France

Recruiting

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Non-Small Cell Carcinoma of Lung, TNM Stage 4

France, Monaco
ETOP IBCSG Partners Foundation
Hoffmann-La Roche

Terminated

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer (ALERT-lung)

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

Ireland, Spain, Belgium, Italy, Netherlands, Switzerland
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Sun Yat-sen University

Completed

Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Mersana Therapeutics

Completed

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

Small Cell Lung Cancer | Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7

United States, Canada
Groupe Français de Pneumo-Cancérologie

Completed

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) (EGFR-RETRO)

NSCLC Non Small Cells Lung Cancer

France
Boehringer Ingelheim

Completed

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Non-squamous, Non-Small Cell Lung Cancer

Japan
Hoffmann-La Roche

Completed

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Spain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
University of Wisconsin, Madison
AstraZeneca

Terminated

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IV

United States
National Cancer Institute, Naples

Active, not recruiting

PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy (PETRA)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB

Italy
European Organisation for Research and Treatment...

Withdrawn

Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) (SOLUTION)

Squamous Non-small Cell Lung Cancer | Non-Squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)

Terminated

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Lung Cancer | Adenocarcinoma of Lung

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); RefleXion...

Completed

Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy

Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage I Lung Cancer | Stage II Lung Cancer | Stage I Non-Small Cell Lung Cancer AJCC v7 | Stage IA Non-Small...

United States
Centre Hospitalier Universitaire, Amiens

Unknown

Evaluation of Serum Procalcitonin Rate in Patients With Stage IV Non-small Cell Lung Cancer in First Line Chemotherapy (KBPCT)

Non Small Cells Lung Cancer

France
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer
University of Southern California
National Cancer Institute (NCI)

Terminated

Collection of Blood Samples in Patients With Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer
Guangzhou University of Traditional Chinese Medicine
Jiangsu Province Hospital of Traditional Chinese Medicine; The First Affiliated...

Not yet recruiting

Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study

Non-small Cell Lung Cancer | Non-Small-Cell Lung Carcinoma

China
Mirati Therapeutics Inc.

Recruiting

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Pancreatic Adenocarcinoma | Solid Tumor | Advanced Solid Tumor | Non-small Cell Lung Cancer | Colo-rectal Cancer

United States

Clinical Trials on Non-Small Cell Lung Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations